Drug intelligence / Profile preview

bupivacaine + tramadol

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Caudal, Epidural, Local Infiltration, Intrathecal

Overview

A combination of bupivacaine, an amide local anesthetic, and tramadol, a centrally acting opioid analgesic. This combination is used for postoperative pain management through various administration routes including caudal blocks, epidural administration, and local infiltration. The combination provides superior and prolonged analgesia compared to either agent alone, with bupivacaine blocking sodium channels to prevent nerve impulse transmission while tramadol works through μ-opioid receptor activation and inhibition of serotonin and norepinephrine reuptake.

Other names: Tramadol + Bupivacaine

Targets

SERT (Sodium-dependent serotonin transporter)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on bupivacaine + tramadol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupivacaine + tramadol.

Explore the full profile